Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

227.00p

Change Today:

-2.00p
52 Week High: 323.00p
52 Week Low: 189.00p

Currency: UK Pounds
Shares Issued: 872.15m
Volume: 12,659

Market Cap: £1,979.78m
RiskGrade: 226

Latest ShareCast News

Hutchmed upbeat on preclinical data for novel cancer therapy

By Josh White

Date: Thursday 23 Oct 2025

(Sharecast News) - Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy HMPL-A251, the first investigational drug to emerge from the company's proprietary Antibody-Targeted Therapy Conjugate (ATTC) platform.

Read full story

News Channel

Hutchmed to present new and updated clinical data

By Josh White

Date: Friday 05 Sep 2025

(Sharecast News) - Hutchmed China said on Friday that new and updated clinical data from several of its drug candidates would be presented at two major oncology meetings this month, including the World Conference on Lung Cancer (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan.

Read full story

News Channel

Hutchmed enrols last patient in phase 3 lung cancer trial

By Josh White

Date: Wednesday 20 Aug 2025

(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment in its phase three 'Sanovo' trial in China testing a combination of 'Orpathys', or savolitinib, and 'Tagrisso', or osimertinib, as a first-line therapy for certain non-small cell lung cancer patients.

Read full story

News Channel

Hutchmed to get milestone payment after China dr...	30-Jun-2025	ShareCast
Hutchmed new drug application accepted in China	05-Jun-2025	ShareCast
Hutchmed China upbeat on results from lung cance...	02-Jun-2025	ShareCast
Hutchmed enrols patients for phase two savolitin...	22-Apr-2025	ShareCast
Hutchmed renal cell carcinoma trial meets primar...	19-Mar-2025	ShareCast
Hutchmed announces progress, hits milestone with...	02-Jan-2025	ShareCast
Hutchmed to receive $10m milestone payment from ...	13-Dec-2024	ShareCast
Hutchmed lung cancer therapy gets breakthrough d...	12-Dec-2024	ShareCast
Hutchmed endometrial cancer treatment gets condi...	03-Dec-2024	ShareCast
Hutchmed partner launches Fruzaqla in Japan	22-Nov-2024	ShareCast
Hutchmed to receive $20m Fruzaqla milestone paym...	31-Oct-2024	ShareCast
Hutchmed reports positive results from AstraZene...	16-Oct-2024	ShareCast
Hutchmed partner Takeda gets Japanese approval f...	24-Sep-2024	ShareCast
Hutchmed to present new and updated clinical tri...	09-Sep-2024	ShareCast
Hutchmed withdraws supplemental new drug applica...	30-Aug-2024	ShareCast
Oncology revenue drives first-half growth for Hu...	31-Jul-2024	ShareCast
Hutchmed gets tazemetostat new drug application ...	04-Jul-2024	ShareCast

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

HCM Market Data

Currency	UK Pounds
Share Price	227.00p
Change Today	-2.00p
% Change	-0.87 %
52 Week High	323.00p
52 Week Low	189.00p
Volume	12,659
Shares Issued	872.15m
Market Cap	£1,979.78m
RiskGrade	226